Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab monotherapy in previously treated AL amyloidosis
NL-OMON59639Phase 2Active, not recruiting
- Sponsor
- European Myeloma Network B.V.
- Start
- Jul 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of teclistamab, sponsored by European Myeloma Network B.V.. Started Jul 2025; status: active, not recruiting.
02
Drugs
teclistamab
Beyond the preview
Go deeper on NL-OMON59639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59639.